Archives

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
JPM analyst explains what could push gold prices up to $6,000
Commodities

JPM analyst explains what could push gold prices up to $6,000

Gold prices have been in a sharp uptrend in 2025 amidst uncertainty related to higher tariffs under the Trump administration and their potential impact on the US economy. Trump tariffs delivered a massive blow to the benchmark S&P 500 index in recent months, which, at one point, was seen trading down about 20% versus its […]

  • May 10, 2025 10:47 AM PDT
  • Invezz
Akero Therapeutics präsentiert auf dem EASL-Kongress 2025 die Ergebnisse nach 96 Wochen der klinischen Phase-IIb-Studie SYMMETRY zu Efruxifermin bei Patienten mit kompensierter Zirrhose, die durch MASH verursacht wird, und zeigt eine Verbesserung der Fibrose ohne Verschlechterung der MASH
Market Updates

Akero Therapeutics präsentiert auf dem EASL-Kongress 2025 die Ergebnisse nach 96 Wochen der klinischen Phase-IIb-Studie SYMMETRY zu Efruxifermin bei Patienten mit kompensierter Zirrhose, die durch MASH verursacht wird, und zeigt eine Verbesserung der Fibrose ohne Verschlechterung der MASH

SOUTH SAN FRANCISCO, Kalifornien, May 10, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), ein in der klinischen Phase tätiges Unternehmen, das bahnbrechende Therapien für Patienten m...

  • May 10, 2025 09:28 AM PDT
  • EODHD
Apple Wants Its $20 Billion, and Is Willing to Throw Google Under the Bus to Keep It
Market Updates

Apple Wants Its $20 Billion, and Is Willing to Throw Google Under the Bus to Keep It

A new brief release from Alphabet’s antitrust trial reads a lot like Eddy Cue’s shocking testimony this past week. Continue Reading View Comments

  • May 10, 2025 09:03 AM PDT
  • EODHD
Tapestry price target raised to $80 from $78 at BMO Capital
Market Updates

Tapestry price target raised to $80 from $78 at BMO Capital

BMO Capital raised the firm’s price target on Tapestry (TPR) to $80 from $78 and keeps a Market Perform rating on the shares. The company reported a top- and bottom-line beat, as better revenues flowe...

  • May 10, 2025 08:00 AM PDT
  • EODHD
Santander dismissed NatWest offer for U.K. retail bank, FT reports
Market Updates

Santander dismissed NatWest offer for U.K. retail bank, FT reports

Earlier this year, Spanish lender Santander (SAN) spurned a bid worth roughly GBP 11B for its U.K. retail bank from NatWest Group (NWG), the Financial Times reports. Santander rejected the offer becau...

  • May 10, 2025 08:00 AM PDT
  • EODHD
Pinterest price target lowered to $40 from $46 at BMO Capital
Market Updates

Pinterest price target lowered to $40 from $46 at BMO Capital

BMO Capital lowered the firm’s price target on Pinterest (PINS) to $40 from $46 and keeps an Outperform rating on the shares after its Q1 results. The company’s continued momentum with lower funnel Ad...

  • May 10, 2025 07:57 AM PDT
  • EODHD
US Foods price target raised to $85 from $80 at BMO Capital
Market Updates

US Foods price target raised to $85 from $80 at BMO Capital

BMO Capital analyst Kelly Bania raised the firm’s price target on US Foods (USFD) to $85 from $80 and keeps an Outperform rating on the shares. The company’s Q1 results were impressive, delivering ind...

  • May 10, 2025 07:55 AM PDT
  • EODHD
Akero Therapeutics gibt Publikation von „Phase IIb SYMMETRY“-Studie im New England Journal of Medicine bekannt
Market Updates

Akero Therapeutics gibt Publikation von „Phase IIb SYMMETRY“-Studie im New England Journal of Medicine bekannt

Die Ergebnisse stützen den potenziellen Nutzen von Efruxifermin (EFX) für eine Fibrosebesserung unter Patienten mit kompensierter Zirrhose (F4-Fibrose) aufgrund von MASH auf Basis von SYMMETRY-Studien...

  • May 10, 2025 07:28 AM PDT
  • EODHD
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
Market Updates

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing body of support around the anti-fibrotic activi...

  • May 10, 2025 07:00 AM PDT
  • EODHD
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.